Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Northwest Biotherapeutics, Inc. (NWBO : OTC)
 
 • Company Description   
Northwest Biotherapeutics, Inc. is a biotechnology company focused on discovering, developing, and commercializing immunotherapy products that safely generate and enhance immune system responses to treat cancer.

Number of Employees: 20

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.68 Daily Weekly Monthly
20 Day Moving Average: 9,644,931 shares
Shares Outstanding: 1,012.83 (millions)
Market Capitalization: $688.62 (millions)
Beta: 0.05
52 Week High: $2.05
52 Week Low: $0.59
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -28.05% -18.97%
12 Week -22.43% -14.73%
Year To Date -2.87% 21.31%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
4800 MONTGOMERY LANE SUITE 800
-
BETHESDA,MD 20814
USA
ph: 240-497-9024
fax: 240-627-4121
lgoldman@nwbio.com http://www.nwbio.com
 
 • General Corporate Information   
Officers
Linda F. Powers - President and Chief Executive Officer
Alton L. Boynton - Director
Navid Malik - Director
Jerry Jasinowski - Director
J. Cofer Black - Director

Peer Information
Northwest Biotherapeutics, Inc. (CORR.)
Northwest Biotherapeutics, Inc. (RSPI)
Northwest Biotherapeutics, Inc. (CGXP)
Northwest Biotherapeutics, Inc. (BGEN)
Northwest Biotherapeutics, Inc. (GTBP)
Northwest Biotherapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 66737P600
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/15/22
Share - Related Items
Shares Outstanding: 1,012.83
Most Recent Split Date: 9.00 (0.06:1)
Beta: 0.05
Market Capitalization: $688.62 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/15/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: 3.57
Price / Sales: 456.65
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: 68.62%
vs. Previous Quarter: -%
ROE
03/31/22 - -75.45
12/31/21 - -63.48
09/30/21 - -
ROA
03/31/22 - 529.04
12/31/21 - 552.82
09/30/21 - -766.65
Current Ratio
03/31/22 - 0.07
12/31/21 - 0.13
09/30/21 - 0.02
Quick Ratio
03/31/22 - 0.07
12/31/21 - 0.13
09/30/21 - 0.02
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -15,549.93
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -15,549.93
Pre-Tax Margin
03/31/22 - 14,459.80
12/31/21 - 17,823.48
09/30/21 - -15,549.93
Book Value
03/31/22 - -0.12
12/31/21 - -0.13
09/30/21 - -0.33
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Capital
03/31/22 - -
12/31/21 - -
09/30/21 - -
 

Powered by Zacks Investment Research ©